Transcriptomics

Dataset Information

0

GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma


ABSTRACT: Lenvatinib is a multiple receptor tyrosine kinases inhibitor (TKI) authorized for first-line treatment of hepatocellular carcinoma (HCC). However, Lenvatinib resistance is common in HCC clinical treatment, highlighting the urgent need to understand mechanisms of resistance. Here, we identified Golgi membrane protein 1 (GOLM1), a type II transmembrane protein originally located in the Golgi apparatus, as a novel regulator of Lenvatinib resistance. We established Lenvatinib resistance in human HCC cell lines PLC/PRF/5. Through RNA-seq, we found that GOLM1 was significantly upregulated, which was further validated in patients derived tumor tissue and peripheral blood. GOLM1 overexpression contributes to Lenvatinib resistance and HCC progression in vitro and in vivo. Mechanistically, GOLM1 upregulates CSN5 expression through EGFR-STAT3 pathway. Reversely, CSN5 deubiquitinates and stabilizes GOLM1 protein by inhibiting ubiquitin-proteasome pathway of GOLM1. Collectively, our data demonstrate that GOLM1 is one of the key driver of Lenvatinib resistance in HCC and depicts a molecular network in Lenvatininb resistant HCC cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE273819 | GEO | 2024/08/07

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-12-24 | GSE192912 | GEO
2023-09-29 | PXD038152 | Pride
2011-12-27 | E-GEOD-26485 | biostudies-arrayexpress
2021-07-22 | GSE157905 | GEO
2023-08-08 | GSE223201 | GEO
2011-12-27 | GSE26485 | GEO
2022-03-23 | GSE186191 | GEO
2022-11-01 | GSE214324 | GEO
2024-08-20 | PXD054805 | Pride
| PRJNA1143404 | ENA